KRAS and non-small cell lung carcinoma: Sotorasib was the first inhibitor of KRAS G12C approved by the FDA [35] and, subsequently, the Therapeutic Goods Administration (TGA) in Australia [36] for use in NSCLC following trials published in 2020 and 2021.